RT Journal Article
SR Electronic
T1 Defining Key Deprescribing Measures from Electronic Health Data: A Multisite Data Harmonization Project
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.06.23298060
DO 10.1101/2023.11.06.23298060
A1 Dublin, Sascha
A1 Albertson-Junkans, Ladia
A1 Pham Nguyen, Thanh Phuong
A1 Pavon, Juliessa M.
A1 Hastings, Susan N.
A1 Maciejewski, Matthew L.
A1 Willis, Allison
A1 Zepel, Lindsay
A1 Hennessy, Sean
A1 Albers, Kathleen B.
A1 Mowery, Danielle
A1 Clark, Amy G.
A1 Thomas, Sunil
A1 Steinman, Michael A.
A1 Boyd, Cynthia M.
A1 Bayliss, Elizabeth A.
YR 2023
UL http://medrxiv.org/content/early/2023/11/07/2023.11.06.23298060.abstract
AB Background Deprescribing, or systematically stopping or reducing risky or unneeded medications, could improve older adults’ health. Electronic health records (EHR) hold promise for supporting deprescribing studies, but there are currently no standardized measures for key variables. With benzodiazepines and other sedative-hypnotics (Z-drugs) as a case study, we developed and examined EHR-based definitions for chronic medication use and discontinuation.Methods We conducted a retrospective cohort study set within 5 U.S. healthcare systems. The study population was adults age 65+ from 2017-2019 with chronic benzodiazepine or Z-drug use, without dementia or serious mental illness. We used EHR data for medication orders and dispensings to define key variables, including chronic benzodiazepine/Z-drug use and discontinuation. We explored definitions for discontinuation based on 1) gaps in medication availability during follow-up (no active order/dispensing) or 2) not having medication available at a fixed time point. We examined the impact of varying gap length from 30 to 180 days, accounting for stockpiling, and requiring a 30-day period without orders/dispensings (“halo”) around the fixed time point. We also compared results from medication orders vs. dispensings for the same population.Results 1.6-2.6% of older adults had chronic use of a benzodiazepine or Z-drug. Depending on the definition and site, the proportion discontinuing use over 12 months ranged from 6% to 49%. Requiring a longer gap in orders/dispensings or a 30-day “halo” around a fixed time point resulted in lower estimates. Orders data were less likely to identify discontinuation than dispensing data.Conclusions Requiring a medication gap of ≥90 days or a 30-day period with no orders/dispensings around a fixed time point may improve the likelihood that an outcome represents true discontinuation. Orders data appear to underestimate discontinuation compared to dispensing data. More work is needed to adapt and test the proposed definitions for other drug classes and care settings.Impact Statement We certify that this work is novel. Prior papers have identified a need for greater standardization of definitions for medication exposure and discontinuation in deprescribing studies. To our knowledge, no prior paper has systematically examined the construction of deprescribing variables from electronic health data. This is the first paper to present standardized definitions for variables needed for deprescribing studies based on electronic health data, to implement these definitions in multiple healthcare systems and data types, and to examine their performance. This is also the first paper to examine the impact of using medication orders vs. dispensing data to define key deprescribing variables.Key pointsUsing benzodiazepines and Z-drugs as a case study, we developed and implemented standardized definitions for key variables needed for deprescribing studies using electronic health records data from 5 diverse U.S. healthcare systems.Requiring a gap of ≥90 days without an active order/dispensing or, for a fixed time point, requiring a period of ≥30 days surrounding it with no order/dispensing will likely increase the accuracy of identifying true medication discontinuation.Applying definitions to medication orders data generated higher estimates of chronic use and lower estimates of medication discontinuation than dispensing data.Why does this paper matter?The use of standardized variable definitions in deprescribing studies will improve the ability to synthesize data and compare results between studies, advancing knowledge and supporting more evidence-based guidelines for clinical care.Competing Interest StatementSD has received funding from GSK. SH has consulted for or received funding from Pfizer, Johnson & Johnson, Novo Nordisk, Arbor Pharmaceuticals, the Medullary Thyroid Cancer Consortium (Novo Nordisk, AstraZeneca, GlaxoSmithKline and Eli Lilly), Biogen, Intercept Pharmaceuticals, Provention Bio, bluebird bio, and Amylyx Pharmaceuticals. TPPN was a member of the 2022-2023 Junior Investigator Intensive Program of the US Deprescribing Research Network, which is funded by the National Institute on Aging, and has received support from Acadia Pharmaceuticals. MM owns stock in Amgen. Other authors have no conflicts to report.Funding StatementThis work was funded by National Institute on Aging grants R24AG064025 and 1K23AG058788-03 (Pavon) and US Department of Veterans Affairs grant RCS 10-391 (Maciejewski).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Kaiser Permanente Washington gave ethical approval for this work. The institutional review boards of the University of Pennsylvania, Duke University (Duke Health) and the Durham VA Medical Center waived ethical approval for this work (that is, determined the work was exempt from IRB review).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData produced in the present study are not available for sharing because they come from electronic health records governed by United States HIPAA regulations and participants did not provide consent for data sharing (data were obtained with a waiver of consent.)